pegfp n1 pgfp Search Results


plasmid pgl4.51  (Promega)
90
Promega plasmid pgl4.51
Plasmid Pgl4.51, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pegfp+n1+pgfp/pgl3+basic/pmc04899101-108-0-13
Average 90 stars, based on 1 article reviews
plasmid pgl4.51 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
trkb constructs  (Addgene inc)
90
Addgene inc trkb constructs
NT‐4/5 inhibits BDNF through upregulation <t>of</t> <t>TrkB.T1</t> and downregulation of TrkB‐FL. A, Western blots of protein expression of TrkB receptors and its phosphorylation in COS7 cells. Primary antibodies dilution in PBS‐tw was p‐TrkB Y816 1:1000 and α‐actin 1:1000 or TBS‐tw total‐TrkB 1:1000. BDNF and NT‐4/5 were used to evaluate the expression of p‐TrkB (145 KDa, 2nd, 4th, 6th, and 8th column), TrkB‐FL (145 KDa, 2nd, 4th, 6th, and 8th column) and TrkB‐T.1 (95 KDa, 3rd, 4th, 7th, 8th) under the BDNF and NT‐4/5 treatments. B, Western blots of protein expression of TrkB receptors isoforms under, BDNF → NT‐4/5 and NT‐4/5 → BDNF treatments. Primary antibodies dilution was 1:10 000. BDNF → NT‐4/5 induced, p‐TrkB of TrkB‐FL (145 KDa, 2nd column), upregulation of TrkB.T1 (95 KDa, 3rd and 4th columns), and downregulation of TrkB‐FL, in addition to reduction in p‐TrkB when both isoforms were coexpressed in COS‐7 cells (4th column). NT‐4/5 → BDNF induced p‐TrkB and TrkB‐FL (6th column), TrkB.T1 (7th column) expression. When the two isoforms were coexpressed in COS 7 cells, TrkB‐FL expression was reduced (8th vs to 6th column), without affecting p‐TrkB and TrkB.T1 (8th column). Control = nontransfected COS‐7 cells. C, Summary of the p‐TrkB/Total‐TrkB‐FL in panel A is presented in the bars. There were no differences in the p‐TrkB level expression to BDNF or NT‐4/5 exposure. D, Summary of the p‐TrkB/Total‐TrkB‐FL from panel B is presented in the bars. There were no differences in the TrkB‐FL level expression, but phosphorylation changed when FL and T.1 isoforms were coexpressed. E, Analysis of optical density of TrkB.T1/TrkB‐FL bands ratio increased for BDNF → NT‐4/5 and NT‐4/5 → BDNF treatments (panel B), compared to BDNF and NT‐4/5 (panel A; F 3,7 = 62.007, P < 0.001, ANOVA with a post hoc Holm Sidak‐method). * P < 0.05
Trkb Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pegfp+n1+pgfp/pEGFP-N1-TrkB+(Plasmid+%2332500)/pmc06488875-46-29-33
Average 90 stars, based on 1 article reviews
trkb constructs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


NT‐4/5 inhibits BDNF through upregulation of TrkB.T1 and downregulation of TrkB‐FL. A, Western blots of protein expression of TrkB receptors and its phosphorylation in COS7 cells. Primary antibodies dilution in PBS‐tw was p‐TrkB Y816 1:1000 and α‐actin 1:1000 or TBS‐tw total‐TrkB 1:1000. BDNF and NT‐4/5 were used to evaluate the expression of p‐TrkB (145 KDa, 2nd, 4th, 6th, and 8th column), TrkB‐FL (145 KDa, 2nd, 4th, 6th, and 8th column) and TrkB‐T.1 (95 KDa, 3rd, 4th, 7th, 8th) under the BDNF and NT‐4/5 treatments. B, Western blots of protein expression of TrkB receptors isoforms under, BDNF → NT‐4/5 and NT‐4/5 → BDNF treatments. Primary antibodies dilution was 1:10 000. BDNF → NT‐4/5 induced, p‐TrkB of TrkB‐FL (145 KDa, 2nd column), upregulation of TrkB.T1 (95 KDa, 3rd and 4th columns), and downregulation of TrkB‐FL, in addition to reduction in p‐TrkB when both isoforms were coexpressed in COS‐7 cells (4th column). NT‐4/5 → BDNF induced p‐TrkB and TrkB‐FL (6th column), TrkB.T1 (7th column) expression. When the two isoforms were coexpressed in COS 7 cells, TrkB‐FL expression was reduced (8th vs to 6th column), without affecting p‐TrkB and TrkB.T1 (8th column). Control = nontransfected COS‐7 cells. C, Summary of the p‐TrkB/Total‐TrkB‐FL in panel A is presented in the bars. There were no differences in the p‐TrkB level expression to BDNF or NT‐4/5 exposure. D, Summary of the p‐TrkB/Total‐TrkB‐FL from panel B is presented in the bars. There were no differences in the TrkB‐FL level expression, but phosphorylation changed when FL and T.1 isoforms were coexpressed. E, Analysis of optical density of TrkB.T1/TrkB‐FL bands ratio increased for BDNF → NT‐4/5 and NT‐4/5 → BDNF treatments (panel B), compared to BDNF and NT‐4/5 (panel A; F 3,7 = 62.007, P < 0.001, ANOVA with a post hoc Holm Sidak‐method). * P < 0.05

Journal: CNS Neuroscience & Therapeutics

Article Title: NT‐4/5 antagonizes the BDNF modulation of corticostriatal transmission: Role of the TrkB.T1 receptor

doi: 10.1111/cns.13091

Figure Lengend Snippet: NT‐4/5 inhibits BDNF through upregulation of TrkB.T1 and downregulation of TrkB‐FL. A, Western blots of protein expression of TrkB receptors and its phosphorylation in COS7 cells. Primary antibodies dilution in PBS‐tw was p‐TrkB Y816 1:1000 and α‐actin 1:1000 or TBS‐tw total‐TrkB 1:1000. BDNF and NT‐4/5 were used to evaluate the expression of p‐TrkB (145 KDa, 2nd, 4th, 6th, and 8th column), TrkB‐FL (145 KDa, 2nd, 4th, 6th, and 8th column) and TrkB‐T.1 (95 KDa, 3rd, 4th, 7th, 8th) under the BDNF and NT‐4/5 treatments. B, Western blots of protein expression of TrkB receptors isoforms under, BDNF → NT‐4/5 and NT‐4/5 → BDNF treatments. Primary antibodies dilution was 1:10 000. BDNF → NT‐4/5 induced, p‐TrkB of TrkB‐FL (145 KDa, 2nd column), upregulation of TrkB.T1 (95 KDa, 3rd and 4th columns), and downregulation of TrkB‐FL, in addition to reduction in p‐TrkB when both isoforms were coexpressed in COS‐7 cells (4th column). NT‐4/5 → BDNF induced p‐TrkB and TrkB‐FL (6th column), TrkB.T1 (7th column) expression. When the two isoforms were coexpressed in COS 7 cells, TrkB‐FL expression was reduced (8th vs to 6th column), without affecting p‐TrkB and TrkB.T1 (8th column). Control = nontransfected COS‐7 cells. C, Summary of the p‐TrkB/Total‐TrkB‐FL in panel A is presented in the bars. There were no differences in the p‐TrkB level expression to BDNF or NT‐4/5 exposure. D, Summary of the p‐TrkB/Total‐TrkB‐FL from panel B is presented in the bars. There were no differences in the TrkB‐FL level expression, but phosphorylation changed when FL and T.1 isoforms were coexpressed. E, Analysis of optical density of TrkB.T1/TrkB‐FL bands ratio increased for BDNF → NT‐4/5 and NT‐4/5 → BDNF treatments (panel B), compared to BDNF and NT‐4/5 (panel A; F 3,7 = 62.007, P < 0.001, ANOVA with a post hoc Holm Sidak‐method). * P < 0.05

Article Snippet: When the cells reached 50%‐60% confluence, the medium was changed to FBS‐free Optimem specialized medium (GIBCO), and the cells were transiently cotransfected with 1 μg of DNA from the TrkB constructs (plasmid pGFP‐N1‐TrkB [Addgene #32500] and pRc/CMV HA‐TrkB.T1 [Addgene #39980]) by using the Lipofectamine® 2000 reagent, following the manufacturer's instructions (Invitrogen).

Techniques: Western Blot, Expressing, Phospho-proteomics, Control